New Product Lunch IMPILO®bexarotene


Bioprofarma Bagó is pleased to introduce IMPILO® bexarotene, for its Hematology Line, replacing the historical TARGRETIN® bexarotene.

Based on its experience to maintain the same quality standards that characterize the company, IMPILO® bexarotene was developed locally, which will benefit supply, helping patients access to continue their treatments.

IMPILO® bexarotene is approved by ANMAT for the treatment of cutaneous manifestations of patients in advanced stages of cutaneous T-cell lymphoma (CTCL) in adult patients resistant to, at least, one previous treatment.

IMPILO® bexarotene is supplied in a single presentation containing 100 75 mg soft capsules.

Now, the treatment of CTCL is with IMPILO®

(Español) Nuevo lanzamiento HUTUS® enzalutamida

(Español) Nos complace presentarles nuestro nuevo producto HUTUS® enzalutamida para cáncer de próstata

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.

26th ARGENTINE CONGRESS OF HEMATOLOGY organized by the Argentine Society of Hematology

Bioprofarma Bagó participated in the 26th Argentine Congress of Hematology 2023, which was held from November 1st to the 4th at its two venues: the Sheraton Hotel and the Costa Galana Hotel, in the City of Mar del Plata.